SLU-PP-332 sits in an unusual position among research compounds: the published pharmacology says one thing about how to deliver it, and most vendors are selling something else. The Billon 2025 paper (PMID 41421047) introduced SLU-PP-915 as an "orally active" sibling specifically because the parent SLU-PP-332 "lacks oral bioavailability." Despite that, the most common vendor formats are oral capsules and tablets — products without published evidence that they produce systemic ERR agonism in humans.
Research-context information only. SLU-PP-332 is an investigational small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) developed at Saint Louis University. It is not approved by the FDA and has not entered human clinical trials. Vendor data, prices, and formats reported below come from public vendor product pages. This article reports what has been documented, not what should be done. Possession or use of investigational compounds outside an authorized research setting may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
This guide is the framework for buying SLU-PP-332 with eyes open: what each vendor sells, what it actually costs per milligram, what a legitimate COA looks like, and which route of administration matches the published preclinical work.
This is not a ranked vendor list — for that, see our Best SLU-PP-332 Vendors. This guide teaches you how to evaluate any vendor yourself.
Understanding SLU-PP-332 Pricing
SLU-PP-332 is a synthetic small molecule, not a peptide. That changes the cost structure. Lyophilized peptide vials and small-molecule oral preparations have different production economics, which is why $/mg varies almost 5× across the vendors we track.
Current Market Pricing (2026)
Five vendor offers across four formats, sorted by published $/mg:
| Vendor | Format | Size | Price | Price Per mg |
|---|---|---|---|---|
| Glacier Aminos | Oral capsules (1 mg × 60) | 60 mg total | $89 | $1.48/mg |
| Dynamic Peptide | Oral capsules (500 mcg × 60) | 30 mg total | $99.99 | $3.33/mg |
| Ion Peptide | Lyophilized injectable vial | 30 mg | $149 | $4.97/mg |
| EZ Peptides | Oral tablets (50 mg × 100 — listed as 50 mg) | 50 mg unit | $368 | $7.36/mg |
| Ion Peptide | Lyophilized injectable vial | 5 mg (currently out of stock) | $39 | $7.80/mg |
The pattern is unusual. Cheapest $/mg is the oral-capsule format from Glacier Aminos at $1.48/mg. The most expensive is also oral, from EZ Peptides at $7.36/mg. The injectable Ion Peptide 30 mg vial sits in between at $4.97/mg.
Looking only at $/mg misses the point. The cheapest-per-mg product (Glacier 60 mg oral capsules) is the same format that the published pharmacology says lacks oral bioavailability. Paying more per milligram for an injectable that has documented IP-route preclinical data may be the better cost-per-effective-mg trade than paying less per milligram for a route with no published systemic exposure data in humans.
Cost Per Week — Reframed Around Route
Mouse studies dosed 25 mg/kg IP twice daily. Allometric scaling to humans is contested and not validated. Community injectable users typically describe far smaller doses than the mouse-scaled equivalent. We will not recommend a human dose — but we can show what a vial of each format yields:
| Format | Yield Per Unit | Vendor | Notes |
|---|---|---|---|
| Injectable 30 mg vial | 30 mg of compound for reconstitution | Ion Peptide | Only format with route consistent with published preclinical pharmacology |
| Oral capsule 1 mg × 60 | 60 mg total split across 60 capsules | Glacier Aminos | Cheap per mg, but Billon 2025 reports parent SLU-PP-332 "lacks oral bioavailability" |
| Oral capsule 500 mcg × 60 | 30 mg total split across 60 capsules | Dynamic Peptide | Same oral-bioavailability concern as Glacier |
| Oral tablet 50 mg | 50 mg per tablet | EZ Peptides | Highest absolute mg per dose unit, same oral concern |
| Sublingual liquid | Varies | Black Lion Research (off-platform) | Marketed as oral-bypass route; no published pharmacokinetic data |
Cross-check the published preclinical doses in our SLU-PP-332 Dosing Guide before committing to any format.
How to Verify SLU-PP-332 Quality
SLU-PP-332 is more lipophilic than most research peptides and synthesized from non-peptide precursors, so the contamination profile and identity-verification approach differ from a peptide product. The COA should confirm both identity (this is SLU-PP-332, not an unrelated small molecule) and purity (98%+).
What a COA (Certificate of Analysis) Should Include
Identity Confirmation
- Mass spectrometry confirming molecular weight ~419.4 Da (molecular formula C22H21N5O3)
- NMR or LC-MS/MS structural confirmation for a small molecule (peptide vendors often skip this — small-molecule identity confirmation is non-negotiable here)
Purity Testing
- HPLC purity — 98%+ minimum
- Single dominant peak on the HPLC chromatogram
Contamination Testing
- Residual solvent panel (DMSO, ethanol, acetone — all common in small-molecule synthesis)
- Heavy metals screen
- Endotoxin testing if the product is positioned for injectable use
How to Verify a COA Is Legitimate
- Match lot number to batch. The COA lot number should match the lot printed on the vial label. Mismatch is a red flag.
- Look for a third-party lab letterhead. Janoshik Analytical and MZ Biolabs are the two most cited. A "COA" generated in-house by the vendor is a self-report, not third-party verification.
- Verify on the lab's site. Both Janoshik and MZ Biolabs publish report-lookup tools. If the COA cannot be verified on the lab's own site, it cannot be trusted.
- Check the date. A COA more than 12 months old does not reflect the current batch. Reputable vendors retest every batch.
- Cross-check the molecular weight. If the COA shows a molecular weight other than ~419.4 Da, the product is not SLU-PP-332.
Red Flags to Avoid
- No COA available on the product page — walk away.
- COA is a screenshot or PDF without third-party lab branding — walk away.
- "Oral SLU-PP-332" marketed with claims of "high oral bioavailability" — that contradicts Billon 2025 (PMID 41421047), which is the paper that explicitly identified the parent compound's lack of oral bioavailability as the reason SLU-PP-915 was developed.
- "SLU-PP-332" priced at less than $1/mg with no COA — pricing this aggressive on a synthesized small molecule suggests cut product or an inert powder being sold under the SLU-PP-332 label.
- Vendor refuses to share COA before purchase — walk away.
